Table 1.
Single Mode Imaging Contrast Agents | ||||
---|---|---|---|---|
Materials | Targets | Imaging Modality | Animal Model | Reference |
mPEG&cRGD-g-PAsp@MnO | cRGD | T1-MRI | A549 tumor-bearing mice | 28 |
PEG-MnO | AS1411 | T1-MRI | 786-0 tumor-bearing mice | 27 |
MnO-TETT-FA | folic acid | T1-MRI | Tiny brain glioma bearing mice | 34 |
MnO modified with PEG | RGD | T1-MRI | M21 tumor-bearing mice | 33 |
MnO@PVP | \ | T1-MRI | Healthy KM mice | 35 |
mPEG-SA-DA@MnO | \ | T1-MRI | A 4-week male ICR mouse | 32 |
MnO@PDns | \ | T1-MRI | Healthy balb/c female mice | 31 |
Multimodal imaging contrast agents | ||||
Materials | Targets | Imaging Modality | Animal Model | Reference |
Fe3O4@MnO/mSiO2-CD133 | CD133 | T1- and T2-MRI | Adult Sprague−Dawley rats | 37 |
Fe3O4/MnO–Cy5.5–CTX | CTX | NIRF/T1- and T2-MRI | Glioma-bearing mice | 44 |
MnO-PEG-Cy5.5 | \ | NIRF/T1-MRI | Glioma-bearing nude mice | 40 |
MnO-TETT | \ | Fluorescence/T1-MRI | Glioma-bearing mice | 42 |
MnO@Au | \ | T1-MR/PA/CT Imaging | HepG2-bearing mice | 45 |
Au@HMSN/Au&MnO-PEI | \ | US/MR/CT Imaging | VX2 tumor–bearing rabbits | 2 |
Nanotheranostic agents | ||||
Materials | Treatment agents | Imaging-guided treatment | Animal model | Reference |
MnO@CNSs | CNSs | MRI-guided PTT | 4T1 tumor-bearing BABL/c mice | 14 |
MWNTs-MnO-PEG | MWNTs | MR and dark dye imaging-guided PTT | Mice exhibiting LNs metastases | 53 |
IR808@MnO | IR808 | NIR fluorescence/PA/MR imaging-guided PTT | MCF-7 cell tumor-bearing nude mice | 54 |
MnO and DTX co-loaded PTNPs | DTX | MR and fluorescence imaging-guided chemotherapy | Human breast cancer MDA-MB-231 tumor-bearing mice | 52 |
USMO@MSNs-Dox | Dox | MRI-guided chemotherapy | HeLa cells-bearing BABL/c nude mice | 51 |
Abbreviations: mPEG, methoxypolyethylene glycols; cRGD, cyclic arginine-glycine-aspartic acid; PAsp, poly(aspartic acid); mPEG&cRGD-g-PAsp, mPEG and cRGD-grafted PAsp; MRI, magnetic resonance imaging; PEG, poly (ethylene glycol); TETT, N-(trimethoxysilylpropyl) ethylene diamine triacetic acid; FA, folic acid; RGD, arginine-glycine-aspartic acid; PVP, poly(vinylpyrrolidone); mPEG-SA-DA, dopamine-terminated mPEG linked with succinic anhydride; PDns, pegylated bis-phosphonate dendrons; mSiO2, mesoporous silica; CTX, chlorotoxin; NIRF, near-infrared fluorescence; PA, photoacoustic; CT, X-ray computed tomography; HMSN, hollow mesoporous silica nanoparticle; PEI, polyethylenimine; US, ultrasound; CNSs, carbonaceous nanospheres; PTT, photothermal therapy; MWNTs, multi-walled carbon nanotubes; DTX, docetaxel; PTNPs, polymeric theranostic nanoparticles; USMO@MSNs, ultrasmall manganese oxide-capped mesoporous silica nanoparticles; Dox, doxorubicin.